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Abstract
Background: PARV4 is a new member of the Parvoviridae family not closely related to any of the known human
parvoviruses. Viremia seems to be a hallmark of PARV4 infection and viral DNA persistence has been demonstrated
in a few tissues. Till now, PARV4 has not been associated with any disease and its prevalence in human population
has not been clearly established. This study was aimed to assess the tissue distribution and the ability to persist of
PARV4 in comparison to parvovirus B19 (B19V).
Results: PARV4 and B19V DNA detection was carried out in various tissues of individuals without suspect of acute
viral infection, by a real time PCR and a nested PCR, targeting the ORF2 and the ORF1 respectively. Low amount of
PARV4 DNA was found frequently (>40%) in heart and liver of adults individuals, less frequently in lungs and
kidneys (23,5 and 18% respectively) and was rare in bone marrow, skin and synovium samples (5,5%, 4% and 5%,
respectively). By comparison, B19V DNA sequences were present in the same tissues with a higher frequency
(significantly higher in myocardium, skin and bone marrow) except than in liver where the frequency was the
same of PARV4 DNA and in plasma samples where B19V frequency was significantly lower than that of PARV4
Conclusions: The particular tropism of PARV4 for liver and heart, here emerged, suggests to focus further studies
on these tissues as possible target for viral replication and on the possible role of PARV4 infection in liver and
heart diseases. Neither bone marrow nor kidney seem to be a common target of viral replication.
Background
PARV4 is a member of the Parvoviridae family discov-
ered in 2005 in plasma from an intravenous drug user,
with symptoms consistent with acute HIV infection, but
confirmed to be HIV RNA negative [1]. It seemed to be
not closely related to any of the known human or ani-
mal parvoviruses until 2008 when novel porcine and
bovine parvoviruses highly similar to PARV4 were iden-
tified so that it was proposed the inclusion of PARV4 in
a new genus Hokovirus [2]. Three genotypes of PARV4
have been identified at present [3,4]. Till now, it has not
been associated with any disease and its spread in the
human population has not been clearly assessed. In fact,
the serological assays for anti-PARV4 antibody
detection, only recently developed, till now have been
applied on small groups of individuals only [5]. Viremia
seems to be a hallmark of PARV4 infection. PARV4 was
found in 5% of plasma pools at levels suggesting the
existence of donations with high viral load [6], in 16% of
clotting factor VIII concentrates [7], in 2% of plasma
samples from healthy donors [8] and in 7,95% of serum
samples from intravenous drug users in Thailand [9].
Several data indicate that the transmission of the virus
predominantly occurs by parenteral route [5,10] whereas
the respiratory transmission seems to be unlikely [11].
As regards tissue distribution, PARV4 DNA was demon-
strated frequently in bone marrow and lymphoid tissue
from HIV infected individuals [12] and also in liver of
non HIV-infected adults [13]. One study reports that
PARV4 DNA can be detected, with a low frequency, in
healthy and pathological skin samples [14].
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It is known that B19V frequently persist in solid tis-
sues in asymptomatic individuals and, less frequently,
also in bone marrow [15].
The aim of this study was to assess whether PARV4 is
able to persist in different tissues, like B19V, or if it
shows a particular tissue tropism.
Results
With the aim to assess the tissue distribution and the
ability to persist of PARV4 in comparison to B19V, we
searched for DNA sequences of both parvoviruses in
various tissues of individuals without suspect of acute
viral infection. Table 1 shows the results of PARV4
DNA detection in different tissues, in comparison with
B19 DNA detection. The frequency of PARV4 DNA
finding was low in skin, synovium and bone marrow (4-
5,5%) whereas in myocardium samples PARV4
sequences were shown in 17 out of 35 (49%), a fre-
quency significantly higher than in the other tissues
examined but significantly lower than that of B19V.
PARV4 DNA was found in 8 out of 39 plasma speci-
mens (20,5%) while B19V DNA was demonstrated in
one of these specimens only (2,5%). It is noteworthy
that these 39 specimens were from 21 immunodepressed
hematological patients and 18 immunocompetent indivi-
duals and the frequency of viremia was 33% (7 positives
out of 21) in the former group and 5,5% (1 positive out
of 18) in the second group (however, this difference is
not statistically significant). The viral load in these sera
was low: below 3,8 × 103copies/ml.
From 17 out the 35 individuals dead for various
causes, without known viral myocarditis or dilated cardi-
omyopathy, lungs, liver, kidney and blood specimens
could be examined, in addition to the myocardium, with
the aim to verify the distribution of PARV4 and B19V
DNA in the different organs of the same individual. In
none of these cases viral DNA was detectable in the
blood while PARV4 as well as B19V DNA were found
frequently in the different organs analyzed (Table 2).
PARV4 DNA was present more frequently in the liver
and in the myocardium (41%) than in lungs and kidneys
(23,5% and 18% respectively). The frequency of PARV4
DNA in the liver was similar to that of B19V DNA in
this tissue and lower in the others. In one individual
PARV4 DNA and in 4 individuals B19V DNA were
demonstrated in myocardium samples only. In one indi-
vidual PARV4 DNA and in 4 individuals B19V DNA
were present in all the tissues examined. In two cases
PARV4 DNA sequences were not demonstrable in the
myocardium and were detectable in other tissues,
whereas B19V infected individuals had always DNA
sequences in the myocardium.
The concentration of PARV4 DNA in all the positive
tissues was generally low, below or near the level of
quantization by the real time PCR here employed, corre-
sponding to ≤ 380 copies/106cells.
As previously reported, the copy number of B19V
DNA varied from below the level of quantization by the
real time PCR to 7 × 104 copies per 106 cells, except for
two myocardium samples where about 106 copies per
106 cells were found (15).
PARV4 sequence analysis, aimed to establish the gen-
otype of PARV4 present in the myocardium samples,
could be performed on 10 isolates only, out of 17 posi-
tive samples, because of the low level of viral DNA. All
were included in the genotype 2 (PARV5) after compari-
son with consensus sequences of the three genotypes
Table 1 Detection of PARV4 DNA in tissues and plasma
in comparison with B19 DNA in the same specimens*
Samples N° PARV4 DNA positive
(%)
B19V DNA positive
(%)
Bone marrow° 26 2 (5,5) 9 (25)
Skin° 25 1 (4) 18 (72)
Sinovyum 21 1 (5) 6 (28,5)
Myocardium° 35 17 (49) 26 (74)
Plasma° 39 8 (20,5) 1 (2,5)
*part of the results of B19 DNA detection have been previously reported (12)
°difference between percentages of PARV4 and B19V DNA statistically
significant
Table 2 Detection of PARV4 and B19V DNA in different
tissues from 17 individuals without known viral
myocarditis or dilated cardiomyopathy
myocardium lung liver kidney
Patient PARV4 B19V PARV4 B19V PARV4 B19V PARV4 B19V
1 - + - - - - - -
2 - - - - - - - -
3 + + - + - - - +
4 - + - - - - - -
5 - + - + - - - +
6 + + - + - - + -
7 + + + + + + - +
8 + + - - + - - -
9 - - - - + - + -
10 + + + + + + - +
11 - + + + + + - +
12 + + - + + + - +
13 - + - - - - - -
14 - + - - - + - -
15 + - + - + - + -
16 - + - - - + - +
17 - + - - - + - +
Tot* 7 (41) 14
(82)
4 (23) 7
(41)
7 (41) 7
(41)
3 (18) 8
(47)
* number of positives (%)
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(GenBank accession numbers HQ245657-HQ245666).
As regards B19V, either genotype 1 or genotype 2 were
present, with a slightly higher frequency of the 2.
PARV4 DNA was undetectable in the urine specimens
of the bone marrow transplantation patients.
Discussion and Conclusions
In this study low amount of PARV4 DNA was found
frequently (>40%) in heart and liver of adults indivi-
duals, less frequently in lungs and kidneys (23,5 and
18% respectively) and was rare in bone marrow, skin
and synovium samples (5,5%, 4% and 5%, respectively).
By comparison, B19V DNA was present in the same tis-
sues with a higher frequency (significantly higher in
myocardium, skin and bone marrow) except than in
liver where its frequency was the same of PARV4 DNA
and in plasma samples where B19V frequency was sig-
nificantly lower than that of PARV4. Some of these
results are fairly in agreement with the literature where
the frequency of PARV4 DNA in bone marrow varies
from 0% (0/8) in HIV uninfected individuals (like the
patients enrolled in this study), to 46% and 65% in HIV
infected patients [12,16] and is 7,7% in the skin of HIV-
negative individuals [14]. The frequency of PARV4 DNA
in the liver reported in literature [13] was lower (15%)
in comparison with 41% in this study. It is to note that
the study of Schneider [13] and the present study are
very different as regards the number and the source of
the specimens analyzed as well as the methods used for
PARV4 DNA detection; in fact in the former study 87
liver specimens, obtained mainly in occasion of liver
transplantation for various causes, were analyzed by four
PCRs. The presence of PARV4 DNA in myocardium
samples is reported here for the first time and with a
high frequency. The viral load was low also in this tissue
and 10 isolates out of the 17 positive myocardium sam-
ples that could be analyzed by sequencing showed to be
genotype 2 (PARV5), a result that could be related with
the age of these patients, all born before 1956 [12], in
agreement also with B19V genotype distribution, as pre-
viously discussed [15].
Low level PARV4 viremia, which seems characteristic
of persistent more than of acute infection, was more
common in hematological immunodepressed patients
(33%), in comparison with 5.5% in immunocompetent
individuals. This result, if confirmed on a larger number
of patients, could indicate that reactivation or persis-
tence of PARV4 may occur under immunodepression
conditions and manifest as viremia more frequently than
B19V. In fact, B19V viremia was not reported in this
group of hematological immunodepressed patients. Con-
sidering that PARV4 DNA was found in bone marrow
from 2 out of 36 hematological patients only (5,5%)
whereas viremia occurred in 7 out of 21 (33%) patients
of the same group, these results could suggest that it is
unlikely that the site of latency/persistence and reactiva-
tion of this virus is the bone marrow. In fact, the two
bone marrow positive patients were also PARV4 DNA
plasma positive, but at least for the other 5 plasma posi-
tive samples another source of viremia has to be
hypothesized. On this point, the failure to detect urinary
PARV4 shedding in the small group of bone marrow
transplantation patients enrolled in this study seems
indicate that viral reactivation in the kidney do not
occur commonly. In addition, the failure to detect
PARV4 DNA in BAL [14] seems indicate that lung is
not a site of viral active infection, despite the presence
of PARV4 sequences in 23% of individuals, as our
results show. Further studies are necessary to detect the
tissue target of PARV4 infection and the results here
reported could suggest to focus in particular on the
liver.
If more than 40% of individuals may have viral DNA
sequences in liver or myocardium the parenteral route
may not be the only way of PARV4 transmission. How-
ever, in agreement with the absence of respiratory trans-
mission, it seems likely that PARV4 infection is less
frequently transmitted than B19V infection and then it
is less frequently detectable in the host tissues. When
PARV4 infection occurs, the virus spreads to various
organs where it can persist, more or less frequently. If
confirmed, the observation that the frequency of PARV4
DNA persistence in the liver is of the same order than
that of B19 DNA, while in all the other tissues here con-
sidered is lower, could indicate that the liver is a main
target of PARV4 infection. Its particular tropism for
myocardium and liver, here reported, suggests to further
study the possible role of PARV4 infection in heart and
liver diseases, considering also that PARV4 infection has
been frequently detected in HCV infected patients. It is
to note that also B19V is frequently detectable in liver
and myocardial tissue both in acute and persistent B19V
infection and its importance in liver and heart diseases
still remains unclear [17-21].
Methods
Clinical samples
Tissue biopsies were collected in 2006, from 72 Italian
adult patients, non HIV-infected, after informed con-
sent: twenty six bone marrow samples from patients
(mean age 60; range: 22-82) with B19-unrelated hemato-
logical disorders referred to the Department of Hema-
tology, submitted to different chemotherapeutic
regimens; twenty one synovial tissue samples from
healthy individuals (mean age:70, range:36-82) who
underwent surgery for arthrosis or joint trauma, referred
to the Department of Orthopedics and Traumatology;
twenty five skin biopsies from patients (mean age: 67,
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range 33-93) with B19-unrelated dermatological lesions,
referred to the Department of Dermatological Sciences.
All the patients were immunocompetent except those
with hematological disorders. From 39 out of the 72
patients a serum sample was collected at the same time
of the biopsy. In addition, from 2006 to 2010, myocar-
dium autoptic samples were obtained from 35 Italian
individuals, non HIV-infected (mean:70, range: 53-84)
without known viral myocarditis or dilated cardiomyo-
pathy. From 17 out of 35 cadavers autoptic samples
from lungs, liver, kidney and blood were also available.
In addition, 93 urine specimens from 29 bone marrow
transplantation recipients, at different times after infu-
sion were obtained for PARV4 DNA detection.
PARV4 DNA detection and sequencing
After DNA extraction using the High Pure PCR Tem-
plate Preparation Kit (Roche, Basel, Switzerland) PARV4
DNA detection was performed by two PCR able to
amplify sequences of the three genotypes. A real time
PCR using the primers PVORF2F and PVORF2R
reported by Fryer (8) and Syber Green as intercalating
dye, was developed for virus detection and viral load
assessment. One μl (25 pmol) of each primer and 5 μl
of extracted DNA were added to 18 μl of Quantitec
SYBR Green PCR Master Mix (Qiagen, Hilden, Ger-
many). A first step of 10 min at 94°C, to activate the
Taq polymerase, was followed by 40 cycles of 94°C for
30 s, 62°C for 30 s, 72°C for 60 s, with a reading step at
79°C for 15 s. The reaction was performed using the
Rotor-Gene 3000 real time apparatus (Corbett Research,
Sidney, Australia).
Melting curve analysis was performed to control the
specificity of the PCR products.
To construct the calibration curve, serial dilutions of
the target sequence, 268 bp long, cloned in the p-GEM-
T vector system (Promega, Milano, Italy) were used.
The range of linearity of the quantitative reaction was
1,96 × 101-1,96 × 106 copies/ml. A real time PCR for
the b-globin gene was performed to calculate the num-
ber of cells of the tissues extracted, as already described
[15]. About 50.000 cells per reaction were analyzed. In
addition, a nested PCR described in literature [8], with
primers targeting a conserved region of ORF1 of the
three known PARV4 genotypes was used to confirm the
results of the previous assay.
The sensitivity of these two assays was similar, both
being able to detect 2 copies of its target/μl in 100% of
cases.
A sample was considered PARV4 DNA positive if
positive by both reactions.
Amplicons obtained by the real time PCR (ORF2) and
by the nested PCR (ORF 1) were sequenced using the
primers PVORF2F and PVORF2R and the inner primers,
respectively. Sequencing was carried out by the dideoxy-
nucleotide chain termination method on an ABI Prism
377 automatic sequencer (Applied Biosystems), using
the ABI PRISM Dye Terminator cycle sequencing Ready
Reaction kit.
B19 DNA detection and genotyping was performed as
previously described [15].
Statistical analysis
The frequencies of PARV4 and B19V DNA positive
samples were compared by the chi-square test with
Yates correction.
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